Britannia Life Sciences Inc.
BLAB
CNSX
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 843.80K | 2.61M | -- | -298.60K | -499.40K |
| Total Depreciation and Amortization | 11.10K | 11.30K | -- | 11.50K | 11.30K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -818.60K | -1.17M | -- | -96.90K | 49.70K |
| Change in Net Operating Assets | -500.60K | -1.79M | -- | 2.30K | -592.00K |
| Cash from Operations | -464.30K | -337.70K | -- | -381.70K | -1.03M |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 7.77M | 0.00 | -- | -3.63M | -180.70K |
| Cash from Investing | 7.77M | 0.00 | -- | -3.63M | -180.70K |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -24.60K | -24.50K | -- | -30.30K | -29.80K |
| Issuance of Common Stock | 140.00K | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 81.20K | -17.60K | -- | -22.00K | -21.60K |
| Foreign Exchange rate Adjustments | 11.40K | 1.20K | -- | 3.40K | -4.30K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 7.40M | -354.10K | -- | -4.03M | -1.24M |